TIVAly: The TI.VA Algorithm: A First-in-Humans Test.

Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Other)
Overall Status
Completed
CT.gov ID
NCT05199883
Collaborator
(none)
5
1
1
2
2.5

Study Details

Study Description

Brief Summary

The TI.VA algorithm is a new method to titrate the anesthetic drug concentrations whenever the planned level of anesthesia results to be not appropriate to blunt the patient's reaction to surgical stimulation.

TI.VA is a multiple inputs/multiple outputs algorithm. The control variables are the bispectral index (BIS) and the mean arterial pressure (MAP) combined in a decision-making matrix. The optimal range for the two control variables (BIS: 540-60 and MAP: 65-75 mmHg) identified the Optimal Anesthesia Zone (OAZ) at the center of the matrix. Any time one or both control variables escape from the PAZ, the algorithm proposes an intervention on the hypnotic and/or opioid levels (algorithm outputs).

A First-in-Humans study was designed to capture preliminary data on the safety and performance of the TI.VA algorithm.

Condition or Disease Intervention/Treatment Phase
  • Other: TI.VA algorithm: decision support system
N/A

Detailed Description

The TI.VA algorithm is a new method to titrate the anesthetic drug concentrations whenever the planned level of anesthesia results to be not appropriate to blunt the patient's reaction to surgical stimulation.

TI.VA is a multiple inputs/multiple outputs algorithm. The control variables are the bispectral index (BIS) and the mean arterial pressure (MAP) combined in a decision-making matrix (DMM). The optimal range for the two control variables (BIS: 540-60 and MAP: 65-75 mmHg) identified the Optimal Anesthesia Zone (OAZ) at the center of the matrix. Any time one or both control variables escape from the OAZ, the algorithm quantifies the inadequacy of anesthesia level through a vector connecting the patient's current position on the DMM to the central point identified by the coordinates BIS= 50 and MAP = 75mmHg. Thereafter, the analysis of the vector main components allows the generation of two coefficients that are used to set out a balanced intervention on the hypnotic and opioid levels (algorithm outputs).

A First-in-Humans study was designed to capture preliminary data on the safety and performance of the TI.VA algorithm This is a prospective study involving a single cohort of patients without major comorbidity and candidate for minor superficial surgery. All patients received Propofol and Remifentanil administered by TCI systems as part of Total Intravenous Anaesthesia.

The algorithm was tested during maintenance of anesthesia defined as the period between skin incision and completion of surgical resection. In this step of the procedure, the titration strategy for anesthetic drug concentrations was suggested by TI.VA algorithm.

Data was collected automatically using dedicated software.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a prospective study involving a series of consecutive patients.This is a prospective study involving a series of consecutive patients.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The TI.VA Algorithm: Vector Analysis Applied to a Decision-Making Matrix to Model the Reactive Control Strategy During General Anesthesia: a First-in-Humans Test.
Actual Study Start Date :
Dec 1, 2020
Actual Primary Completion Date :
Jan 31, 2021
Actual Study Completion Date :
Jan 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: TI.VA group

The titration of Propofol and Remifentanil levels will be guided by TI.VA algorithm in the time between skin incision and completion of surgical resection.

Other: TI.VA algorithm: decision support system
TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.

Outcome Measures

Primary Outcome Measures

  1. Adverse Events [during the surgical procedure intervention]

    An adverse event is defined as any untoward medical occurrence in the study period. Intra-operative adverse events were reported using the institutional incident reporting system. Data was collected in the time between skin incision and the completion of surgical resection.

Secondary Outcome Measures

  1. Stability of the Control Variables [during the surgical procedure intervention]

    To characterize the patient's repose to surgery, the TI.VA algorithm uses a Decision-Making Matrix drawn by crossing BIS (Min-max: 0-100, optimal range 40-60 ) and Mean Arterial Pressure (Min-max: 0-150mmHg. Optimal range 65-75mmHg). The Optimal anesthesia zone is defined as the area of the Decision-Making Matrix identify by the optimal range for the two control variables (BIS and MAP). The stability of the control variables during anesthesia was quantified by the percentage of monitoring points registered in the Optimal Anaesthesia Zone during anesthesia. A monitoring point is understood as a value of BIS and MAP recorded at the same time. The system records a monitoring point every 5 seconds. Data was collected in the time between skin incision and the completion of surgical resection.

  2. Performance Error analysis [during the surgical procedure intervention]

    The performance of the algorithm was assessed using the performance error (PE), median PE (MDPE), median absolute PE (MDAPE), and wobble according to the method of Performance Error. Data was collected in the time between skin incision and the completion of surgical resection.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
The inclusion criteria were: :
  • age 18-65 years at the time of recruitment.

  • candidates for curative surgery for breast cancer.

  • American Society of Anaesthesiologists (ASA) status I/II.

The exclusion criteria were:
  • ASA status > II.

  • counter-indications for use of the drugs employed in this protocol.

  • pregnancy or lactation.

  • incapacity to understand the study explanation and sign the informed consent form.

These criteria were selected according to the risk mitigation strategy described in the protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy 20133

Sponsors and Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Investigators

  • Principal Investigator: Emiliano Tognoli, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Emiliano Tognoli, Principal Investigator, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier:
NCT05199883
Other Study ID Numbers:
  • INT150/20
First Posted:
Jan 20, 2022
Last Update Posted:
Feb 3, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Emiliano Tognoli, Principal Investigator, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Study Results

No Results Posted as of Feb 3, 2022